Novolytics - Bacteriophage Assets' Unit Acquisition

Novolytics - Bacteriophage Assets raised a round of funding on January 08, 2016. Investors include AmpliPhi Biosciences.

Novolytics, formed in 2002, engages in the research, development, and production of phage therapy products to combat antibiotic resistance.…

Articles about Novolytics - Bacteriophage Assets' Unit Acquisition: